Home › Funds › Sessa Capital IM, L.P. › SABS

Sessa Capital IM, L.P. position in SABS

SAB BIOTHERAPEUTICS INC · Health Care

Sessa Capital IM, L.P. reported holding 2,198,457 shares of SABS (SAB BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$8.6M, representing 0.14% of its reported portfolio and ranking #26 among its reported holdings. Sessa Capital IM, L.P. has disclosed SABS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)2.20M sh
Reported value held$8.57M
Portfolio Weight0.14%
First reportedQ4 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Sessa Capital IM, L.P.'s SABS position evolved

Sessa Capital IM, L.P. first disclosed a stake in SABS in Q4 2023 at 4,584,571 shares (US$3.2M). The position peaked in Q2 2026 at 2,198,457 shares, worth US$8.6M. Across 11 filings, Sessa Capital IM, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 2,198,457 shares valued at US$8.6M. Notable position changes include a 90% trim in Q1 2024 (shares fell 32% over the following quarter), a 380% increase in Q3 2025 (shares rose 86% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 4.58M $3.15M New
Q1 2024 458.46K $2.08M Reduce
Q2 2024 458.46K $1.42M Hold
Q3 2024 458.46K $1.24M Hold
Q4 2024 458.46K $1.74M Hold
Q1 2025 458.46K $623.50K Hold
Q2 2025 458.46K $804.59K Hold
Q3 2025 2.20M $4.42M Add
Q4 2025 2.20M $8.22M Hold
Q1 2026 2.20M $8.42M Hold
Q2 2026 2.20M $8.57M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SABS and 13F data

SABS (SAB BIOTHERAPEUTICS INC) is a Health Care company. 77 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Vivo Capital, LLC (US$28.5M), Commodore Capital LP (US$11.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SABS

All SABS fund holders →

FAQ

How long has Sessa Capital IM, L.P. held SABS?

Sessa Capital IM, L.P. has disclosed SABS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is Sessa Capital IM, L.P.'s current position in SABS?

As of Q2 2026, Sessa Capital IM, L.P. holds 2.20M shares of SABS (SAB BIOTHERAPEUTICS INC), valued at $8.57M, representing 0.14% of its reported portfolio and ranking #26.

Has Sessa Capital IM, L.P. been buying or selling SABS?

In the latest 13F filing (Q2 2026), Sessa Capital IM, L.P. held unchanged its position in SABS. The position peaked in Q2 2026 at 2.20M shares.

Which other funds hold SABS?

Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, Commodore Capital LP, among 77 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.